ABIH-3733 is under clinical development by Assembly Biosciences and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect ABIH-3733’s likelihood of approval (LoA) and phase transition for Hepatitis B took place on 23 Nov 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their ABIH-3733 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
ABIH-3733 is under development for the treatment of chronic hepatitis B virus infection. It acts by targeting capsid protein. The drug candidate is formulated as liquid and solid dosage forms and administered through oral route. It is developed based on core protein allosteric modulators (CpAMs) platform.
Assembly Biosciences overview
Assembly Biosciences (Assembly), formerly Ventrus Biosciences is a biotechnology company that develops, discovers, and commercializes small molecule therapies. The company develops therapies for the treatment of infectious diseases such as microbiotic therapies for Clostridium difficile (C. difficile) infections (CDI) and chronic hepatitis B virus (HBV). It also develops Gemicel platform technology that helps for targeted oral delivery vaccines, small molecules, live biotherapeutics, and complex macromolecules that are aimed for specific region in gastrointestinal tract (GI). Assembly’s HBV Cure program target’s the chronic hepatitis B virus infection. The company owns and operates its research and development facilities located in Indiana, New York, and California, the US. Assembly is headquartered in South San Francisco, the US.
Quick View ABIH-3733 LOA Data
|Highest Development Stage|